Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Mohamad Moussa, Athanasios Papatsoris, Despoina Sryropoulou, Mohamed Abou Chakra, Athanasios Dellis & Lazaros Tzelves. (2021) A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer. Expert Opinion on Pharmacotherapy 22:13, pages 1685-1728.
Read now
Read now
Mohamad Moussa, Lazaros Lazarou, Athanasios Dellis, Mohamed Abou Chakra & Athanasios Papatsoris. (2021) An up-to-date evaluation of darolutamide for the treatment of prostate cancer. Expert Opinion on Pharmacotherapy 22:4, pages 397-402.
Read now
Read now
Johanna Svensson, Ingela Franck Lissbrant, Oskar Gauffin, Marie Hjälm-Eriksson, Suzanne Kilany, Karin Fagerlund & Pär Stattin. (2021) Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden. Scandinavian Journal of Urology 55:1, pages 1-8.
Read now
Read now
Articles from other publishers (15)
Dong Ren & Guannan Zhang. 2024. Therapy Resistance in Prostate Cancer. Therapy Resistance in Prostate Cancer
137
155
.
Khurram Rehman, Zoya Iqbal, Deng Zhiqin, Hina Ayub, Naseem Saba, Muzammil Ahamd Khan, Liang Yujie & Li Duan. (2023) Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer. Cancer Cell International 23:1.
Crossref
Crossref
Tingyu Wu, Yanshuang Zhang, Qing Han, Xin Lu, Yirui Cheng, Jiachen Chen, Jianjun Sha & Weiliang Xia. (2023) Klotho-beta attenuates Rab8a-mediated exosome regulation and promotes prostate cancer progression. Oncogene 42:38, pages 2801-2815.
Crossref
Crossref
Neha Thakur, Sameer Quazi, Bindu Naik, Saurabh Kumar Jha & Pallavi Singh. (2023) New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics. Frontiers in Oncology 13.
Crossref
Crossref
Huichuan Tian, Yao Zhang, Jiajun Ren, Chaoran Wang, Ruiyu Mou, Xiaojiang Li & Yingjie Jia. (2023) Developing a Core Outcome Set for Assessing Clinical Safety Outcomes of Prostate Cancer in Clinical Trials of Traditional Chinese Medicine: Protocol for a Mixed Methods Study. JMIR Research Protocols 12, pages e46794.
Crossref
Crossref
Qi Jiang, Juan Li, Jingyue Wang & Weibing Zhang. (2023) Inhibition of CDKL3 downregulates STAT1 thus suppressing prostate cancer development. Cell Death & Disease 14:3.
Crossref
Crossref
Mariana C. S. Mancini, Ana P. Morelli, Matheus B. Severino, Isadora C. B. Pavan, Érika P. Zambalde, Mariana M. Góis, Luiz G. S. da Silva, Nathalia Quintero‐Ruiz, Caio F. Romeiro, Daniel F. G. dos Santos, Rosângela M. N. Bezerra & Fernando M. Simabuco. (2022) Knockout of NRF2 triggers prostate cancer cells death through ROS modulation and sensitizes to cisplatin. Journal of Cellular Biochemistry 123:12, pages 2079-2092.
Crossref
Crossref
Feyisola P. Olatunji, Michael Pun, Jacob W. Herman, Oscar Romero, Mitchell Maniatopoulos, Joseph D. Latoche, Robert A. Parise, Jianxia Guo, Jan H. Beumer, Carolyn J. Anderson & Clifford E. Berkman. (2022) Modular Smart Molecules for PSMA-Targeted Chemotherapy. Molecular Cancer Therapeutics 21:11, pages 1701-1709.
Crossref
Crossref
Ze Gao, Jun Huang, Zhaoxiang Xie, Peikun Xin, Hao Huang, Tao Du, Jun Wu & Hai Huang. (2022)
Delivery of enzalutamide
via
nanoparticles for effectively inhibiting prostate cancer progression
. Biomaterials Science 10:18, pages 5187-5196.
Crossref
Crossref
Kangzhe Xie, Keely Tan & Matthew J. Naylor. (2022) Transcription Factors as Novel Therapeutic Targets and Drivers of Prostate Cancer Progression. Frontiers in Oncology 12.
Crossref
Crossref
Xiaozhen Ji, Kai Liu, Qingyue Li, Qun Shen, Fangxuan Han, Qingmei Ye & Caijuan Zheng. (2022) A Mini-Review of Flavone Isomers Apigenin and Genistein in Prostate Cancer Treatment. Frontiers in Pharmacology 13.
Crossref
Crossref
Hiroki Kobayashi, Masaki Shiota, Nobuaki Sato, Satoshi Kobayashi, Takashi Matsumoto, Keisuke Monji, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Ken-ichiro Shiga, Akira Yokomizo & Masatoshi Eto. (2021) Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients. Anti-Cancer Drugs 33:1, pages e541-e547.
Crossref
Crossref
Rajeev K. Singla, Chandragiri Siva Sai, Hitesh Chopra, Sahar Behzad, Himangini Bansal, Rajat Goyal, Rupesh K. Gautam, Christos Tsagkaris, Shikha Joon, Shailja Singla & Bairong Shen. (2021) Natural Products for the Management of Castration-Resistant Prostate Cancer: Special Focus on Nanoparticles Based Studies. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Fabrizio Fontana & Patrizia Limonta. (2021) Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer. Cells 10:5, pages 1133.
Crossref
Crossref
Ding Wang, Xiaodong Wei, Dhan V. Kalvakolanu, Baofeng Guo & Ling Zhang. (2021) Perspectives on Oncolytic Salmonella in Cancer Immunotherapy—A Promising Strategy. Frontiers in Immunology 12.
Crossref
Crossref